人诱导多能干细胞 （iPSC） 承载着无限潜力，它能重编程为多种细胞类型，为疾病治疗、药物筛选乃至个性 化医疗带来曙光。在iPSC的研究和应用中， 科研人员常常 陷入细胞培养扩增的困境 ： iPSC细胞较为"娇贵"，对培养条件极为敏感和苛刻，稍有不慎就会分化，失去多能性和自我更新能力；培养基成分复 杂且价格昂贵，不同批次的iPSC可能存在分化效率、增殖速率或基因稳定性差异，影响实验重复性和下游应用。 以下文章来源于OriCell细胞生物学 ，作者赛业云课堂 OriCell细胞生物学 . OriCell是赛业旗下致力于各种细胞、培养基试剂及干细胞技术服务的子品牌，致力于帮大家把细胞养的 更漂亮，在这里，我们将与你一起探讨培养细胞崽崽的"养娃之道"，让你的细胞也能成为别人家的细 胞！ 因此， 选择合适的iPSC培养方法和优化培养体系至关重要 。 为 综合探讨iPSC的构建、培养扩增和应用 ，赛业生物将于 6月24日 开展 "初识诱导多能干细胞 （iPSC） ：从细胞培养到常见应用"云课堂 ， 赛业OriCell 产品应用科学家 黄增慷博士 将带领大家学习 iPSC的前世今生及前沿应用，并直iPSC培养痛点 ， 步 ...

Core Insights - A groundbreaking study published in "Cell Stem Cell" reveals that a team from Tokyo University of Science has established a culture system for induced pluripotent stem cells (iPSCs) from chimpanzee somatic cells, marking a significant advancement in the study of early primate embryonic development [1][2] - The research uncovers key mechanisms that maintain the self-renewal capacity of these cells and successfully creates a chimpanzee blastocyst model, simulating early embryonic structures [1][3] Group 1 - Understanding how cells differentiate during early embryonic stages is crucial for advancing regenerative medicine and developmental biology [1] - Pluripotent stem cells (PSCs) have significant value due to their potential to transform into various cell types, but research has been hindered by ethical and technical limitations regarding human and other primate studies [1][2] - The study identifies that inhibiting the Polycomb Repressive Complex 2 (PRC2) is essential for the growth of chimpanzee iPSCs, as cells cannot proliferate without this inhibition [1][2] Group 2 - Chimpanzee iPSCs exhibit a high degree of similarity in gene expression patterns and differentiation potential compared to human cells, capable of forming both embryonic and extra-embryonic tissues, which are critical for successful implantation and subsequent development [2] - The team has developed the first feeder-free culture system for chimpanzee iPSCs, achieving long-term stable expansion of these cells using PRC2 inhibitors, thus eliminating reliance on external feeder cells [2][3] Group 3 - The establishment of the chimpanzee blastocyst model provides a powerful platform for scientists to explore the molecular mechanisms of early mammalian embryonic development [3] - This model is expected to facilitate advancements in reproductive biology, disease modeling, drug screening, and personalized regenerative medicine [3] - The findings expand the understanding of the initial stages of life and pave new pathways for future primate stem cell research [3]

以下文章来源于36氪Pro ，作者胡香赟 海若镜 36氪Pro . 36氪旗下官方账号。深度、前瞻，为1%的人捕捉商业先机。 低 帕金森病发病根源在于 患者脑部多巴胺能神经元的大规模凋续。 文 ｜ 胡香赟 编辑 ｜ 海若镜 来源｜ 36氪Pro（ID：krkrpro） 封面来源 ｜ Pexels 36氪获悉，从事细胞治疗药物开发的"睿健医药"近期完成过亿元B+轮融资。本轮融资由丰川资本领投，荷塘创投跟投，易凯资本 任独家财务顾问。募集资金将用于加速推进公司核心产品管线的中美临床试验、多款创新管线的研发和临床能力搭建。 另据了解，此前不久，睿健医药刚刚获得B轮融资。两轮B系列融资累计募资超2亿元。 睿健医药成立于2017年，聚焦于小分子化学转录调控诱导多能干细胞（iPSC）产品开发，也是36氪长期追踪的一家企业。近期， 在接连完成大额募资之余，睿健医药自主研发的用于帕金森治疗的核心产品管线NouvNeu001（一款化学诱导的功能型人源多巴 胺能神经元前体细胞）已经于近期启动II期临床。 借着这个契机，我们回访了睿健医药创始人、CEO魏君，聊了聊公司的业务进 展，以及对干细胞赛道发展的期待。 帕金森病是一种常见的 ...